Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Pfizer, AbbVie and Bristol-Myers Squibb all have blockbuster drugs due to lose exclusivity soon and have recently sealed multibillion-dollar deals....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...‘Once bitten, twice shy’ Before the pandemic, Pfizer and Sanofi had both begun to dabble in mRNA vaccines through partnerships — but Pfizer’s partner BioNTech was far further along than Sanofi’s partner...
...The first person to be vaccinated at King’s, 98-year-old Kenneth Coley, said: “I’m very pleased I’ve been chosen, I thought I’d be too old.”...
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Mr Spink bought the property for £65.5m in 2013 in partnership with the private equity investors Evans Randall....
...Kenneth Frazier, Merck’s chairman and chief executive, said he anticipated some pressure on the company’s more mature brands in China — but overall he was “very confident” about growth in the country....
...GSK and Pfizer are uniting and spinning off their consumer health divisions, which sell over-the-counter products, while Pfizer is in the process of trying to combine its generics business Upjohn with the...
...“We believe that we’ve only scratched the surface in terms of the opportunity in key markets such as China,” Merck’s chief executive Kenneth Frazier said on its earnings call....
...Kenneth C. Frazer, Merck chairman and chief executive, said it was a “strong start to 2019”....
...Kenneth Frazier, chief executive of Merck, said prices would come down if the system was changed so that no one company faced a disadvantage....
...In December, GSK said it was hiving off its consumer division and debt into a joint venture with Pfizer....
...Kenneth Frazier, chairman and chief executive, said increasing the dividend and authorising additional opportunistic share repurchases were “driven by our commitment to a balanced capital allocation strategy...
...Think Merck CEO Kenneth Frazier’s resignation from President Trump’s American Manufacturing Council in response to the president’s lame handling of racial violence in Charlottesville....
...Kenneth Copeland Ministries (KCM), which carries the name of the Texan televangelist who founded it, is a proud owner of a Gulfstream V private jet....
...Kenneth Glueck, Oracle senior vice-president, wrote to the lawmakers: “Your legislation does not, as suggested by the bill’s opponents, usher the end of the internet....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...Trump on jobs The tweets vs the facts Merck Donald Trump praised Merck in July when the drugmaker said it would invest $4bn to create as many as 4,000 jobs, along with Pfizer and Corning....
...Thomas Kenneth Whitaker, known as Ken, was born in December 8 1916 — eight months after the Easter Rising that would lead to the creation of the Republic of Ireland — in Rostrevor, a town in what is now...
...Kenneth Jacobs, chief executive of Lazard, says: “The last cycle, toward the end, was skewed toward financial sponsor activity....
...Pfizer shares, which have lagged behind Merck’s, slipped 0.3 per cent to $34.48....
...But on the day Mr Read set out Pfizer’s position, Kenneth Frazier, chief executive of Merck, set himself apart by declaring that he was not interested in deals “solely or primarily for the purposes of tax...
...(Financial Times) Pfizer snub triggers recrimination at Astra: “Pfizer’s pursuit of AstraZeneca was hanging by a thread on Monday after its “final” £69.4bn offer was rejected by the UK company, sparking...
International Edition